Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."

Original title: “Akeso, Summit drug extends survival in closely watched lung cancer trial”

Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17. The new target action date is November 17.

Original title: “FDA delays verdict on Beren’s rare disease drug by three months”

EMA’s Emergency Task Force (ETF) has recommended updating COVID-19 vaccines to target the new SARS-CoV-2 variant XFG for the 2026/2027 vaccination campaign.XFG is part of the…

Original title: “ETF recommends updating COVID-19 vaccines to target XFG variant”

The findings supporting bepiroversen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

Original title: “GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’”

The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for at least six months after stopping treatment.

Original title: “GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients”

Decnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer.

Original title: “AbbVie snags FDA's first ADC approval for ultra-rare blood cancer”

The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.

Original title: “FDA delays decision on AstraZeneca breast cancer pill”

The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in muscular dystrophy more broadly.

Original title: “FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug”

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

Original title: “Early data for heart drug affirm Lilly’s billion-dollar bet on Verve”

Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer

Original title: “Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen”

Findings strengthen rationale for EMERALD trial of engineered macrophage therapy RTX001

Original title: “Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis”